Trastuzumab deruxtecan in the treatment of HER2-positive metastatic breast cancer

Summary. On November 27, 2025, as part of the 6th International Oncology Congress, AstraZeneca held a Satellite Forum entitled «Beyond Boundaries: Witness the Birth of Innovation in Breast Cancer Therapy». The event focused on discussing the transformative impact of antibody–drug conjugates (ADCs) on treatment strategies for metastatic breast cancer (mBC), particularly the HER2-positive and HER2-low subtypes. The emergence of ADCs, including T-DXd, marks the beginning of a new era of personalized oncology, offering substantial improvements in prognostic outcomes for patients. The Forum confirmed the need for rapid integration of this highly evidence-based therapeutic option into national clinical guidelines.


Log in Registration Search for: Home Electronic publication Fresh number Archives Authors About Edition Subscription Requirements for authors Reviewing Editorial board
Organization of anticancer fight Tumors of the chest cavity Tumors of abdominal organs Tumors of skin, soft tissues, bones Breast tumor Oncogynecology Tumors of the head and neck Oncurology Oncohematology Radiation diagnostics, radiation therapy Experimental studies Magazine online All news	Full article in pdf format Keywords: ADC, antibody–drug conjugates, breast cancer, ENHERTU®, HER2-positive/HER2-low subtype, T-DXd, trastuzumab deruxtecan Review: Share: All electronic publications 2026-01-14 : Conference materials Trastuzumab deruxtecan in the treatment of HER2-positive metastatic breast cancer Summary. On November 27, 2025, as part of the 6th International Oncology Congress, AstraZeneca held a Satellite Forum entitled «Beyond Boundaries: Witness the Birth of Innovation in Breast Cancer Therapy». The event focused on discussing the transformative impact of antibody–drug conjugates (ADCs) on treatment strategies for metastatic breast cancer (mBC), particularly the HER2-positive and HER2-low subtypes. The emergence of ADCs, including T-DXd, marks the beginning of a new era of personalized oncology, offering substantial improvements in prognostic outcomes for patients. The Forum confirmed the need for rapid integration of this highly evidence-based therapeutic option into national clinical guidelines. Follow us on social media: Статьи по теме: Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer (review) Erlotinib efficacy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer Induction targeted therapy with tyrosine kinase inhibitors in the treatment of EGFR-positive non-small cell lung cancer. Clinical case and discussion of features of therapeutic «targeted» tumor pathomorphosis Prognostic factors of metastatic luminal (Her2/neu-negative) breast cancer No Comments » Add your Leave a comment Name (required) Mail (will not be published) (required) Website CAPTCHA Code
MORION Publishing House Editorial office and publisher: 02140, Kyiv, ave. Bazhana 10A Tel.: 380 (44) 585-97-10 Specialized medical online publication for doctors, pharmacists, pharmacists, medical students and pharmaceutical universities.Disclaimer morion.ua apteka.ua pharmstandart.com.ua compendium.com.ua proximaresearch.com

Magazine online

Trastuzumab deruxtecan in the treatment of HER2-positive metastatic breast cancer

No Comments » Add your

Leave a comment